Compare Cassava Sciences Inc (FLNA) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PAGSEG Inc — how do they compare? Cassava Sciences Inc trades at $0.81 (market cap $39.40M), while PAGSEG Inc trades at $10.92 (market cap $2.94B). The key difference: PAGSEG Inc is far larger — about 74.6× Cassava Sciences Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and PAGSEG Inc for 26 Days on average.
| FLNA | PAGS | |
|---|---|---|
Market Cap | $39.40M | $2.94B |
Volume | 759,018 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $4.64 | $12.00 |
52-Week Low | $0.68 | $8.44 |
Typical Hold Time | 37 Days | 26 Days |
Enterprise Value | -$43.28M | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong profitability with a 10.45% net income margin and trades at a discounted valuation with a P/E of 7.1 and P/S of 0.74. Recent earnings beat expectations in Q2 2026, and a $0.28 dividend is scheduled for September 2026.
The outlook is positive given undervaluation, profitability, and dividend yield, but risks include a recent earnings miss in Q1 2026 and a projected negative net cash flow for 2026. Investor sentiment is supported by strong analyst buy ratings, though technical indicators show some overbought conditions with RSI at 78.08.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
